Full-Time

Employment Counsel

Updated on 5/26/2026

Biogen

Biogen

5,001-10,000 employees

Develops therapies for neurological disorders

Compensation Overview

$226k - $311k/yr

+ Bonus + Equity Incentives

Cambridge, MA, USA

In Person

Category
Legal & Compliance
Requirements
  • Bachelor's degree and J.D.
  • At least 10 years of experience in employment law, including top-tier law firm practice and preferably in-house experience.
  • Licensed to practice law in Massachusetts or eligible for admission.
  • Extensive knowledge of US employment laws and HR compliance.
  • Proven experience in managing investigations, employment disputes and selecting outside counsel.
  • Strong analytical and decision-making skills.
Responsibilities
  • Provide high-quality legal advice to the Global HR team on employment law compliance.
  • Manage employment disputes, including handling demand letters and agency complaints.
  • Oversee global HR governance program, policy rollouts, audits, and vendor contracting.
  • Offer legal counsel on U.S. HR matters such as compensation, benefits, and restructuring.
  • Direct and advise on HR investigations, ensuring thorough and compliant processes.
  • Monitor and advise on employment law developments, anticipating potential impacts.
  • Collaborate with HR, Legal & Compliance, and Finance on non-employee and tax-related issues.
  • Select and manage outside counsel for employment dispute resolutions and other advice.
  • Conduct HR audits, directing necessary remediations for compliance.
  • Develop training materials and update policies in response to legal developments.
  • Facilitate cross-border movement of personnel with legal compliance.
Desired Qualifications
  • Experience with global HR laws and regulations, cross-border personnel movement and international HR compliance.

Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1978

Simplify Jobs

Simplify's Take

What believers are saying

  • Leqembi delivered $168 million in Q1 2026, up 74%.
  • Felzartamab expands Biogen's kidney and immunology pipeline in Greater China.
  • Apellis adds a kidney-disease asset and deepens rare-disease exposure.

What critics are saying

  • Tecfidera generic erosion is accelerating across major regions.
  • Tysabri biosimilars threaten pricing and volumes in Europe and the United States.
  • Italy's antitrust probe creates legal, commercial, and reputational exposure.

What makes Biogen unique

  • Biogen focuses on neurology, immunology, and rare diseases.
  • Founded in 1978, it built deep neuroscience R&D expertise.
  • Its pipeline targets difficult-to-treat disorders with transformative therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Biogen who can refer or advise you

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Pharma Focus Asia
Apr 21st, 2026
Biogen Inc. to invest in felzartamab rights in Greater China through agreement with TJ Biopharma.

Biogen Inc. to invest in felzartamab rights in Greater China through agreement with TJ Biopharma. Tuesday, April 21, 2026 Biogen Inc. has entered into a definitive agreement to invest in the exclusive rights to felzartamab held by TJ Biopharma in the Greater China region. Following the agreement, Biogen will hold exclusive global rights to the drug candidate, which is currently under Phase 3 clinical evaluation for several immune-mediated diseases. Under the terms of the deal, TJ Biopharma will receive an upfront payment of $100 million. The company is also eligible for up to $750 million in milestone payments linked to commercial and sales performance, taking the total potential value of the agreement to $850 million. In addition, TJ Bio will earn royalties in the mid-single-digit to low-double-digit percentage range on net sales in the Greater China region. Biogen plans to record the upfront payment as an acquired in-process research and development expense in the second quarter of 2026. As part of the transaction, Biogen will also take over milestone and royalty obligations tied to an earlier licensing agreement with MorphoSys, a subsidiary of Novartis. Biogen had earlier secured global rights to felzartamab, excluding Greater China, through its acquisition of HI-Bio in July 2024. The company has since initiated Phase 3 trials targeting conditions such as antibody-mediated rejection in kidney transplant patients, IgA nephropathy, and primary membranous nephropathy, with plans to expand into additional indications. The agreement builds on ongoing collaboration between the two companies. In April 2025, TJ Bio joined two global Phase 3 trials sponsored by Biogen, focusing on IgA nephropathy and primary membranous nephropathy in China. Both conditions are major contributors to kidney disease in the country, with a large patient population affected. Biogen will continue to lead clinical development in immunology, and will also take responsibility for manufacturing and commercial activities for felzartamab in the Greater China region. A biologics licence application for felzartamab, submitted by TJ Bio in December 2024 for the treatment of multiple myeloma, is currently under review by the National Medical Products Administration. Following approval, Biogen will oversee post-approval activities in the region, while TJ Bio will act as the manufacturing partner for this indication at its Hangzhou GMP plant.

Genetic Engineering and Biotechnology News
Apr 10th, 2026
Drugs from a text prompt, Wegovy pill competition dampens Lilly's surge.

Drugs from a text prompt, Wegovy pill competition dampens Lilly's surge. April 10, 2026 From designing drugs with a simple text prompt to running experiments guided by extended reality, a new wave of agentic AI is transforming the modern lab. Its editors discuss the latest autonomous systems accelerating biological discovery. In business deals, Gilead Sciences has acquired Tubulis in a transaction worth up to $5 billion, strengthening the buyer's position in antibody-drug conjugates for cancer. Correspondingly, Eli Lilly and Biogen are each making billion-dollar-plus bets, acquiring Centessa, a sleep disorder drug developer, and Apellis, known for its work in immunology and rare diseases. Its episode rounds out by unpacking the dynamic obesity drug market, where intensifying competition from Novo Nordisk's Wegovy pill is prompting Lilly to temper the 2026 sales outlook for its oral obesity drug, Foundayo. Listed below are links to the GEN stories referenced in this episode of Touching Base:

Benzinga
Apr 7th, 2026
Biogen taps Alloy platform to push antisense drug pipeline forward.

Biogen taps Alloy platform to push antisense drug pipeline forward. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. Biogen Inc. (NASDAQ:BIIB) on Tuesday entered into an agreement with Alloy Therapeutics Inc. to accelerate the development of antisense therapies targeting multiple undisclosed indications. Waltham, Massachusetts-based Alloy will receive an upfront payment and stands to earn additional milestone-based compensation, along with tiered royalties on any commercialized products arising from the partnership. Expanding rna-targeted drug development. Alloy's AntiClastic ASO platform is designed to improve the effectiveness of antisense therapeutics by enabling drug developers to target disease pathways at the RNA level within cells. The approach seeks to address longstanding challenges in the field, particularly around drug potency and therapeutic index. Historically, antisense drugs have faced limitations due to poor biodistribution, which has constrained their clinical efficacy. Alloy's broader technology ecosystem. Alloy Therapeutics operates a diversified platform model aimed at accelerating drug discovery. Its ecosystem integrates multiple technologies, including computational and AI-driven tools, to enhance therapeutic development and optimization. The collaboration with Biogen reflects continued interest in leveraging advanced platforms to improve drug discovery efficiency and expand the potential of RNA-based therapeutics. In January 2025, Alloy Therapeutics inked a target-specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi SA (NASDAQ:SNY) for a central nervous system (CNS) target. In return, Sanofi paid an upfront license fee and near-term preclinical milestone payments up to $27.5 million. Alloy is also eligible to receive discovery, development, and commercial milestone payments of over $400 million. Biogen expands portfolio with Apellis deal. Last week, Biogen agreed to acquire Apellis Pharmaceuticals Inc. (NASDAQ:APLS) for $41 per share in cash or approximately $5.6 billion. The acquisition is expected to enhance Biogen's growth portfolio in immunology and rare diseases. The deal consideration includes a contingent value right (CVR) for each share. It allows shareholders to receive two payments of $2 per share based on certain sales thresholds for Apellis. BIIB Stock Price Activity: Biogen shares closed at $172.34 on Monday, according to Benzinga Pro data. Everyone Bought NVIDIA. The Smart Money Is Now Buying What NVIDIA Needs to Run. The chip trade is crowded. Valuations are stretched. The investors who made money on Phase 1 of AI are already repositioning into the one thing every data center depends on: uninterrupted power. Natural gas and nuclear are the only sources that can deliver it at scale - and one small company just landed a deal to power multiple new hyperscale data centers. Posted In: Discover Private Market Opportunities Join 385,000+ Investors

Business Wire
Apr 7th, 2026
Biogen licenses Alloy's AntiClastic™ ASO platform for multi-target antisense drug development

Alloy Therapeutics has entered a collaboration and licence agreement with Biogen for use of its AntiClastic ASO Platform to develop antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for milestone payments and tiered royalties on resulting products. The AntiClastic ASO platform addresses potency and therapeutic index challenges that have historically limited antisense drugs due to biodistribution constraints. The technology combines improvements in primary sequence with proprietary spatial conformation of nucleic acids to enhance delivery to target RNA whilst mitigating inflammatory responses. Alloy Therapeutics is a biotechnology ecosystem company that provides access to AI-powered drug discovery platforms and scientific expertise across multiple therapeutic modalities, including antibodies, bispecifics, genetic medicines and cell therapies.

Yahoo Finance
Apr 3rd, 2026
GoDaddy and Biogen struggle despite cash flow, Champion Homes surges with 29.4% EPS growth

Biogen, a pioneer in neurological treatments, faces significant headwinds despite its 20.7% free cash flow margin. The company's sales have declined 6% annually over the past five years, with earnings per share falling 14.2% annually during the same period. Founded in 1978, Biogen develops therapies for multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and rare diseases. However, its products face end-market challenges, and diminishing returns on capital suggest earlier profit pools are drying up. Trading at $177.40 per share, or 11.6x forward price-to-earnings, Biogen illustrates that strong cash flow alone doesn't guarantee superior returns when underlying business fundamentals weaken.